Results 61 to 70 of about 1,482,131 (288)
, 2019 Oral mucositis is the inflammation of the mouth that affects hundreds of thousands cancer patients as a result of treatment, especially in patients with head and neck cancer. This paper will focus on the comprehension of the development of oral mucositis
Quijano, Lisseth
core +1 more source
Effectiveness of cryotherapy in preventing oral mucositis in pediatric cancer patients in Jordan: a randomized controlled trial [PDF]
Child Health Nursing ResearchPurpose The study aimed to evaluate the effectiveness of cryotherapy in preventing oral mucositis in pediatric patients receiving chemotherapy. Methods An evidence-based practice project utilized a randomized control trial design with two groups ...
Khadeja Banat +4 more
doaj +1 more source
Toward Fit‐for‐Purpose Data for Drug Assessment in Non‐small Cell Lung Cancer: A Core Dataset
Clinical Pharmacology &Therapeutics, EarlyView.Considering the high unmet medical need in people with non‐small cell lung cancer (NSCLC), the drug assessment for targeted therapies often rely on small populations and single‐arm trials, challenging the evaluation by regulatory authorities, health technology assessment bodies (HTAb), and clinicians.
Geeske F. Grit +6 more
wiley +1 more source
Treatment of oral mucositis due to chemotherapy [PDF]
, 2016 Introduction: The management of oral mucositis is a challenge, due to its complex biological nature. Over the last 10 years, different strategies have been developed for the management of oral mucositis caused by chemotherapy in cancer patients. Material
Bagán Sebastián, José Vicente +1 more
core
Clinical Pharmacology &Therapeutics, EarlyView.Exposure‐response analyses supported a favorable benefit‐risk profile of Dato‐DXd at 6 mg/kg Q3W in patients with advanced nonsquamous NSCLC. Datopotamab deruxtecan (Dato‐DXd) is a trophoblast cell‐surface antigen‐2 (TROP2)‐directed antibody‐drug conjugate (ADC) that has demonstrated clinical activity in patients with NSCLC who have received prior ...
Ying Hong +10 more
wiley +1 more source
Actual duration of patient-reported mucositis: Far longer than 2 to 4 weeks and may be avoidable altogether [PDF]
Korean Journal of Clinical Oncology, 2016 The impression that oral mucositis is a brief 14–28 day-consequence of chemoradiation is misguided. Clinically significant patient-reported oral mucositis may last 46 to 102 days depending on the treatment schedule and the modality used.
Ricky Wayne McCullough
doaj +1 more source
Next‐Generation CAR‐T Cell Therapy: From Modular Design to Clinical Expansion
Exploration, EarlyView.Over the past decades, chimeric antigen receptor (CAR)‐T cell therapy has evolved from a linear engineering concept into a powerful yet constrained immunotherapy, limited by tumour microenvironment barriers, immune evasion, and manufacturing complexity.
Yuesong Bai +5 more
wiley +1 more source
PLoS ONEBackgroundOral mucositis is an inflammatory condition of oral cavity which is a common and serious side effect of cancer treatment. Severe oral mucositis compromises basic functions like eating and swallowing causing malnutrition also affecting overall ...
Asad Allana +4 more
doaj +1 more source
Depressive symptoms and oral mucositis in children with oncological diseases: a cross-sectional study [PDF]
Brazilian Oral ResearchThe aim of this study was to investigate the correlation between depressive symptoms and the occurrence of oral mucositis in children with oncological diseases treated at a reference hospital.
Felipe Barreto LEMOS +7 more
doaj +1 more source
Head &Neck, EarlyView.ABSTRACT Purpose To evaluate the efficacy and safety of stereotactic body radiation therapy (SBRT) in previously untreated primary mucosal head and neck cancer (HNC) patients unfit for conventional radiation therapy. Materials and Methods Retrospective analysis of previously unirradiated primary SCC mucosal HNC patients treated with SBRT from 2011 to ...
Mohammed Aldohan +10 more
wiley +1 more source